Skip to main content

Table 1 Baseline characteristics in HCAP patients treated with vancomycin or linezolid

From: Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia

  Overall Linezolid Vancomycin P-valuea
Patients, n 1211 265 946 N/A
Year of hospitalization, n (%)
 2001–2004 541 (44.7) 153 (57.7) 388 (41.0) <0.0001
 2005–2007 670 (55.3) 112 (42.3) 558 (59.0)
Age (years), median (IQR) 76 (70–80) 76 (70–80) 76 (70–81) 0.892
Male, n (%) 1189 (98.2) 259 (97.7) 930 (98.3) 0.537
Race, n (%)
 White 961 (79.4) 225 (84.9) 736 (77.8) 0.033
 Black 188 (15.5) 32 (12.1) 156 (16.5)
 Other 62 (5.1) 8 (3.0) 54 (5.7)
Hispanic ethnicity, n (%) 159 (13.1) 10 (3.8) 149 (15.7) <0.0001
VHA priority group, n (%)
 1 280 (23.1) 45 (17.0) 235 (24.8) 0.019
 2–6 859 (70.9) 200 (75.5) 659 (69.7)
 7–8 72 (6.0) 20 (7.5) 52 (5.5)
HCAP risk factors, n (%)
 Hospitalization within 90 days 941 (77.7) 191 (72.1) 750 (79.3) 0.013
 Nursing home resident within 90 days 36 (3.0) 7 (2.6) 29 (3.1) 0.719
 Hemodialysis 514 (42.4) 112 (42.3) 402 (42.5) 0.947
 Outpatient IV antibiotics within 90 days 152 (12.6) 22 (8.3) 130 (13.7) 0.018
>1 HCAP risk factor, n (%) 384 (31.1) 62 (23.4) 322 (34.0) 0.001
Charlson comorbidity score, median (IQR) 4 (2–6) 4 (2.5–5.5) 4 (2-6) 0.233
Comorbid conditions, n (%)
 Myocardial infarction 121 (10.0) 34 (12.8) 87 (9.2) 0.081
 Heart failure 381 (31.5) 103 (38.8) 278 (29.4) 0.003
 Cerebrovascular disease 302 (24.9) 59 (22.3) 243 (25.7) 0.255
 Chronic obstructive pulmonary disease 614 (50.7) 164 (61.9) 450 (47.6) <0.0001
 Liver disease 16 (1.3) 1 (0.4) 15 (1.6) 0.128
 Chronic kidney disease 523 (43.2) 114 (43.0) 409 (43.2) 0.950
 Diabetes 442 (41.6) 90 (39.0) 352 (42.2) 0.376
 Neoplastic disease 433 (35.8) 92 (34.7) 341 (36.0) 0.690
 HIV/AIDS 4 (0.3) 1 (0.4) 3 (0.3) 0.880
Substance abuse or dependence, n (%)
 Tobacco use 401 (33.1) 100 (37.7) 301 (31.8) 0.070
 Alcohol abuse or dependence 49 (4.0) 11 (4.2) 38 (4.0) 0.922
Medication use within 90 days, n (%)
 Cardiovascular medications 796 (65.7) 196 (74.0) 600 (63.4) 0.001
 Anti-diabetic medications 309 (25.5) 78 (29.4) 231 (24.4) 0.098
 Inhaled corticosteroids 236 (19.5) 67 (25.3) 169 (17.9) 0.007
 Systemic corticosteroids 321 (26.5) 87 (32.8) 234 (24.7) 0.008
 Pulmonary medications 431 (35.6) 123 (46.4) 308 (32.6) <0.0001
Noninvasive mechanical ventilation, n (%) 24 (2.0) 3 (1.1) 21 (2.2) 0.262
Organ failure, n (%) 266 (22.0) 45 (17.0) 221 (23.4) 0.027
Pathogens with a prevalence ≥1 %, n (%)
 Staphylococcus aureus 87 (7.2) 4 (1.5) 83 (8.8) 0.019
 Methicillin-resistant S. aureus 66 (5.5) 5 (1.9) 61 (5.0) 0.004
 Streptococcus pneumoniae 32 (2.6) 8 (3.0) 24 (2.5) 0.005
 Pseudomonas 55 (4.5) 7 (2.6) 48 (5.1) 0.569
 Klebsiella pneumoniae 16 (1.3) 0 (0.0) 16 (1.7) 0.152
  1. HCAP healthcare-associated pneumonia
  2. aItalics indicates statistical significance